Zanidatamab (zani), a HER2-targeted Bispecific Antibody, in Combination with Docetaxel As First-Line Therapy (1L) for Patients (pts) with Advanced HER2-positive Breast Cancer (BC): Updated Results from a Phase Ib/II Study.
JCO Global Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined